The effect of different doses of 32P in the treatment of primary thrombocytosis.
We report on a follow up in 23 patients with primary thrombocytosis treated with two different doses of 32phosphorus phosphate (32P). Ten patients with essential thrombocytosis (ET) received 2 mCi and 13 patients with polycythemia vera (PV) received the standard dose of 0.1 mCi/kg b.w. The patients were listed as having a complete response (CR), partial response (PR) or no response (NR) considering platelet count at 3 and 12 months after 32P injection. The results indicate the existence of a clear correlation of the rate of remission with the 32P injected dose. PV patients show, in fact, a percentage of complete remission higher than ET patients. However, the use of higher doses induces more early and long-term complications.
M L
ML
Randi
F
F
Fabris
L
L
Varotto
P
P
Peverelli
A
A
Girolami
D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use*; D010976:Platelet Count; D011087:Polycythemia Vera / Q000532:radiotherapy; D013920:Thrombocythemia, Essential / Q000532:radiotherapy; D013922:Thrombocytosis / Q000532:radiotherapy*
D010761:Phosphorus Radioisotopes